Factors Likely to Have Influenced Earnings Results Erytech Pharma (NASDAQ:ERYP)

0
152

Earnings results for Erytech Pharma (NASDAQ:ERYP)

Erytech Pharma S.A. is expected* to report earnings on 09/22/2020 before market open. The report will be for the fiscal Quarter ending Jun 2020.

Analyst Opinion on Erytech Pharma (NASDAQ:ERYP)

1 Wall Street analysts have issued ratings and price targets for Erytech Pharma in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Dividend Strength: Erytech Pharma (NASDAQ:ERYP)

Erytech Pharma does not currently pay a dividend. Erytech Pharma does not have a long track record of dividend growth.

Insiders buying/selling: Erytech Pharma (NASDAQ:ERYP)

In the past three months, Erytech Pharma insiders have not sold or bought any company stock. Only 7.24% of the stock of Erytech Pharma is held by institutions.

Earnings and Valuation of Erytech Pharma (NASDAQ:ERYP

Earnings for Erytech Pharma are expected to grow in the coming year, from ($2.63) to ($2.32) per share. The P/E ratio of Erytech Pharma is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Erytech Pharma is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Erytech Pharma has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here